Galera Therapeutics, Inc. Common Stock
GRTX
GRTX was delisted on the 3rd of June, 2024.
36 hedge funds and large institutions have $1.37M invested in Galera Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 8 closing their positions.
3% less funds holding
Funds holding: 37 → 36 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
27% less capital invested
Capital invested by funds: $1.88M → $1.37M (-$511K)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Atom Investors
Austin,
Texas
|
+$70.2K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$56.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$55.4K |
| 4 |
STA
Summit Trail Advisors
New York
|
+$29.1K |
| 5 |
Millennium Management
New York
|
+$15.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$448K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$116K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$51.2K |
| 4 |
Renaissance Technologies
New York
|
-$46K |
| 5 |
VF
Virtu Financial
New York
|
-$8K |
GRTX Hedge Fund Activity: Q1 2024 in Review
36 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q1 2024, worth a combined $1.37M — down 27% from $1.88M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GRTX and 7 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 5 added.
The largest buyer was Atom Investors, opening a new position worth an estimated $70.2K. The largest seller was Sofinnova Investments, exiting entirely with an estimated $448K sold.
- 36 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q1 2024, down from 37 in Q4 2023.
- Funds reported $1.37M of Galera Therapeutics, Inc. Common Stock stock for Q1 2024, down 27% quarter-over-quarter.
- 7 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q1 2024 and 8 closed out, a net change of -1 holder.
- The largest Galera Therapeutics, Inc. Common Stock buyer in Q1 2024 was Atom Investors, an estimated $70.2K added.
- The largest Galera Therapeutics, Inc. Common Stock seller in Q1 2024 was Sofinnova Investments, an estimated $448K sold.
Based on aggregated 13F filings for Q1 2024.